Nuevolution AB received Nasdaq Stockholm's approval to list on the stock exchange's main market.

Nuevolution said Nasdaq Stockholm's approval is subject to customary closing conditions, including approval and registration of a prospectus by the Swedish Financial Supervisory Authority.

The company's shares are expected to trade on Nasdaq Stockholm beginning June 25, while its shares will be delisted from Nasdaq First North Premier on June 21.

Carnegie Investment Bank was the financial adviser and Advokatfirman Vinge was the legal adviser in the transaction.

Copenhagen-based Nuevolution is engaged in the development of drug treatments for oncology and chronic inflammatory diseases.